000268492 001__ 268492
000268492 005__ 20240808164605.0
000268492 020__ $$a978-1-0716-3773-9 (print)
000268492 020__ $$a978-1-0716-3774-6 (electronic)
000268492 0247_ $$2doi$$a10.1007/978-1-0716-3774-6_1
000268492 0247_ $$2pmid$$apmid:38427184
000268492 0247_ $$2ISSN$$a1064-3745
000268492 0247_ $$2ISSN$$a1940-6029
000268492 0247_ $$2altmetric$$aaltmetric:160272602
000268492 037__ $$aDZNE-2024-00238
000268492 041__ $$aEnglish
000268492 082__ $$a570
000268492 1001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b0$$eFirst author$$udzne
000268492 245__ $$aBlood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings.
000268492 260__ $$aNew York, NY$$bSpringer US$$c2024
000268492 29510 $$aBiomarkers for Alzheimer’s Disease Drug Development / Perneczky, Robert (Editor) ; New York, NY : Springer US, 2024, Chapter 1 ; ISSN: 1064-3745=1940-6029 ; ISBN: 978-1-0716-3773-9=978-1-0716-3774-6 ; doi:10.1007/978-1-0716-3774-6
000268492 300__ $$a3 - 14
000268492 3367_ $$2ORCID$$aBOOK_CHAPTER
000268492 3367_ $$07$$2EndNote$$aBook Section
000268492 3367_ $$2DRIVER$$abookPart
000268492 3367_ $$2BibTeX$$aINBOOK
000268492 3367_ $$2DataCite$$aOutput Types/Book chapter
000268492 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1710403714_24480
000268492 4900_ $$aMethods in Molecular Biology$$v2785
000268492 520__ $$aAs our knowledge about the biology of Alzheimer's disease (AD) expands and we recognize the significance of early intervention for effective treatment, there is a shift in focus toward detecting the disease at an early stage. AD is characterized by the accumulation of misfolded amyloid-β (Aβ) and phosphorylated tau proteins in the brain, leading to the formation of senile plaques and neurofibrillary tangles. While a definitive diagnosis of AD can only be confirmed through autopsy by examining these pathological features, there are now reliable methods available for diagnosing the disease in living individuals. These methods involve analyzing cerebrospinal fluid and using positron emission tomography to accurately assess the presence of Aβ and tau proteins. While these diagnostic markers have shown high accuracy in memory-clinic populations, they do have limitations such as the requirement for invasive lumbar puncture or exposure to ionizing radiation. Additionally, they are not easily accessible outside of specialized healthcare settings. Blood-based biomarkers of the core pathological features of AD are being developed, showing promise for less invasive, scalable identification of AD cases in the community. The advantages for the healthcare systems of this development are obvious, but the diagnostic performance of blood-based biomarkers in broader, non-selected populations outside of retrospective analyses and research cohorts still requires further investigation, including the combination with more effective neuropsychological assessments such as digital cognitive test solutions.
000268492 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000268492 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000268492 588__ $$aDataset connected to CrossRef Book Series, PubMed, , Journals: pub.dzne.de
000268492 650_2 $$2MeSH$$aHumans
000268492 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000268492 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000268492 650_2 $$2MeSH$$aRetrospective Studies
000268492 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000268492 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000268492 650_7 $$2Other$$aEarly diagnosis of Alzheimer’s disease and dementia
000268492 650_7 $$2Other$$aEarly diagnosis of Alzheimer’s disease and dementia
000268492 650_7 $$2Other$$aEarly and targeted treatment and prevention of neurodegeneration
000268492 650_7 $$2Other$$aEarly diagnosis of Alzheimer’s disease and dementia
000268492 650_7 $$2Other$$aPatient and service user value
000268492 650_7 $$2Other$$aScalable diagnostic technologies
000268492 650_7 $$2Other$$aSubjective cognitive impairment and mild cognitive impairment
000268492 650_7 $$2NLM Chemicals$$atau Proteins
000268492 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000268492 650_7 $$2NLM Chemicals$$aBiomarkers
000268492 7001_ $$aHansen, Niels$$b1
000268492 7001_ $$0P:(DE-2719)2814244$$aHofmann, Anna$$b2$$udzne
000268492 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b3$$udzne
000268492 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b4$$udzne
000268492 7001_ $$aGrimmer, Timo$$b5
000268492 7001_ $$aFrölich, Lutz$$b6
000268492 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b7$$udzne
000268492 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b8$$udzne
000268492 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b9$$eLast author$$udzne
000268492 7001_ $$aGroup, German Network Memory Clinics- Diagnostic Tools Working$$b10$$eCollaboration Author
000268492 773__ $$a10.1007/978-1-0716-3774-6_1
000268492 8564_ $$uhttps://pub.dzne.de/record/268492/files/DZNE-2024-00238_Restricted.pdf
000268492 8564_ $$uhttps://pub.dzne.de/record/268492/files/DZNE-2024-00238_Restricted.pdf?subformat=pdfa$$xpdfa
000268492 909CO $$ooai:pub.dzne.de:268492$$pVDB
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814244$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000268492 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000268492 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000268492 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000268492 9141_ $$y2024
000268492 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000268492 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000268492 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000268492 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x1
000268492 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x2
000268492 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x3
000268492 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x4
000268492 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x5
000268492 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x6
000268492 980__ $$acontb
000268492 980__ $$aVDB
000268492 980__ $$aI:(DE-2719)1410006
000268492 980__ $$aI:(DE-2719)5000022
000268492 980__ $$aI:(DE-2719)1210001
000268492 980__ $$aI:(DE-2719)1210000
000268492 980__ $$aI:(DE-2719)5000007
000268492 980__ $$aI:(DE-2719)5000006
000268492 980__ $$aI:(DE-2719)1011102
000268492 980__ $$aUNRESTRICTED